These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 9444439)

  • 21. Efficacy of doxazosin in normotensive and hypertensive patients with benign prostatic hyperplasia.
    Kirby RS
    Scand J Urol Nephrol Suppl; 1995; 168():29-33. PubMed ID: 7541549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice.
    Chung BH; Hong SJ; Lee MS
    Int J Urol; 2005 Feb; 12(2):159-65. PubMed ID: 15733110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Doxazosin gastrointestinal therapeutic system: a review of its use in benign prostatic hyperplasia.
    Goldsmith DR; Plosker GL
    Drugs; 2005; 65(14):2037-47. PubMed ID: 16162024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist.
    Beduschi MC; Beduschi R; Oesterling JE
    Urology; 1998 Jun; 51(6):861-72. PubMed ID: 9609620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expanding role of alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia.
    Kirby RS
    Int J Clin Pract; 1998 Sep; 52(6):402-7. PubMed ID: 9894377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia.
    Fitzpatrick JM; Desgrandchamps F
    BJU Int; 2005 Mar; 95(4):575-9. PubMed ID: 15705083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia.
    Cao Y; Wang Y; Guo L; Yang X; Chen T; Niu H
    Med Sci Monit; 2016 Jun; 22():1895-902. PubMed ID: 27260129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience.
    Chapple CR
    Eur Urol; 1996; 29(2):129-44. PubMed ID: 8647139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of doxazosin in men with benign prostatic hyperplasia: urodynamic assessment.
    Ozbey I; Aksoy Y; Polat O; Biçgi O; Demirel A; Okyar G
    Int Urol Nephrol; 1999; 31(4):471-9. PubMed ID: 10668942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Tonocardin (doxazosin) in treating lower urinary tract symptoms].
    Mazo EB; Chepurov DA
    Urologiia; 2003; (3):15-6. PubMed ID: 12846089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia.
    Bhardwa J; Goldstraw M; Tzortzis S; Kirby R
    Expert Opin Pharmacother; 2007 Jun; 8(9):1337-44. PubMed ID: 17563267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia.
    Kirby RS
    Br J Clin Pract Suppl; 1994 May; 74():23-8. PubMed ID: 7519438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolerability of alpha-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: a pooled analysis of seven double-blind, placebo-controlled studies.
    Kaplan SA; D'Alisera PM
    J Gerontol A Biol Sci Med Sci; 1998 May; 53(3):M201-6. PubMed ID: 9597052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Terazosin, doxazosin, and prazosin: current clinical experience.
    Akduman B; Crawford ED
    Urology; 2001 Dec; 58(6 Suppl 1):49-54. PubMed ID: 11750252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Doxazosin in the treatment of benign prostatic hypertrophy: an update.
    Wilt TJ; MacDonald R
    Clin Interv Aging; 2006; 1(4):389-401. PubMed ID: 18046916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medical therapy for benign prostatic hyperplasia: a review of the literature.
    Clifford GM; Farmer RD
    Eur Urol; 2000 Jul; 38(1):2-19. PubMed ID: 10859436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
    McConnell JD; Roehrborn CG; Bautista OM; Andriole GL; Dixon CM; Kusek JW; Lepor H; McVary KT; Nyberg LM; Clarke HS; Crawford ED; Diokno A; Foley JP; Foster HE; Jacobs SC; Kaplan SA; Kreder KJ; Lieber MM; Lucia MS; Miller GJ; Menon M; Milam DF; Ramsdell JW; Schenkman NS; Slawin KM; Smith JA;
    N Engl J Med; 2003 Dec; 349(25):2387-98. PubMed ID: 14681504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Doksazozin "Cardura" in acute urinary retention caused by benign prostatic hyperplasia].
    Perepanova TS; Kamalov AA; Siniukhin VN; Gorokhnov AV; Khazan PL; Orlova EV
    Urologiia; 2001; (3):18-20. PubMed ID: 11505534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The clinical and flowmetric results of the treatment of benign prostatic hyperplasia with doxazosin].
    Salinas Casado J; Esteban Fuertes M; Virseda Chamorro M; Ramírez Fernández JC; Salomon Moh'd S; Luengo Alpuente S; Resel Estévez L
    Arch Esp Urol; 1999 Sep; 52(7):739-48. PubMed ID: 10540764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of doxazosin in patients with mild, intermediate, and severe benign prostatic hyperplasia.
    Mobley DF; Dias N; Levenstein M
    Clin Ther; 1998; 20(1):101-9. PubMed ID: 9522108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.